Page 17 - Nasdaq Cbay News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Advances strategy to partner seladelpar for PBC outside U.S. Brings in approximately $34.0 million upfront payment Japan represents an important market...

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) – Research analysts at Oppenheimer increased their FY2022 earnings estimates for CymaBay Therapeutics in a research report issued to clients and investors on Sunday, August 14th. Oppenheimer analyst J. Olson now anticipates that the biopharmaceutical company will post earnings of ($1.36) per share for the year, up from […]

Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) have received a consensus recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has […]

Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) have earned an average recommendation of “Buy” from the eight research firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) – Investment analysts at Oppenheimer issued their Q1 2022 earnings per share estimates for CymaBay Therapeutics in a research report issued on Friday, March 18th. Oppenheimer analyst J. Olson expects that the biopharmaceutical company will post earnings of ($0.32) per share for the quarter. Oppenheimer also issued estimates […]